Tripep’s new rights offering oversubscribed

The preliminary result from Tripep’s rights offering shows that it has been oversubscribed with significant marginal (approximately 150%). Through the offering Tripep will receive approximately 17.8 MSEK before emission costs. The final outcome of the emission will be presented around the 30th of December 2009.

Those who have subscribed for shares without rights will be allotted shares according to the principles outlined in the prospectus. Notice of allotments will be around the 30th of December 2009 and only given to those who receive shares. After the emission the number of shares in Tripep will increase by 35,575,314 up to 71,150,628. Tripep’s share capital increases with 1,067,259.42 SEK to 2,134,518.84 SEK. ”The interest in the present offering has exceeded expectations. It is delightful that both our present shareholders as well as new potential shareholders have shown us such high interest. The money from the emission makes it possible for us to develop our projects according to plan during 2010 and it is with great excitement we look ahead for an eventful new year. We wish all our shareholders a Merry Christmas and a Happy New Year”, says Tripep’s CEO Anders Vahlne. For more information, please contact: Anders Vahlne, CEO and Head of Research, Tripep AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail: anders.vahlne@ki.se Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s Website: www.tripep.se. In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.